FDA’s NAIN Programme for Alzheimer’s Prevention
The FDA’s new NAIN programme launches with the Alzheimer’s Prevention Accelerator. Explore the implications for clinical trials, biomarkers, and development strategy.
CRA-CRC Training for Closing the Sponsor-Site Gap
CRA-CRC training can rebuild sponsor-site trust that remote monitoring weakened. Find out what a 2026 study found and how clinical teams can act on it.
Clinical Trial Changes and Protocol Amendments
Protocol amendments can rescue studies or weaken evidence. Learn how sponsors can distinguish justified adaptation from costly drift in clinical development.
What Changes in EMA GVP Module III Revision 2?
GVP Module III Revision 2 took effect on 10 September 2026. See what changes for subcontractor oversight, PSMF access, remote inspections, and risk planning.
Clinical Trials in Depression Reveal New R&D Priorities in 2026
Clinical trials in depression reveal a broader R&D landscape, from antidepressants and NMDA approaches to biological data and precision psychiatry.
Ivonescimab Challenges Keytruda Beyond China
Ivonescimab beat pembrolizumab in a Chinese trial. Pharmatica examines what HARMONi-2 means for global clinical development, trial design, and NSCLC treatment.